Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 118-127

  Ho, Han Kiat ^a   Pok, Sharon ^a   Streit, Sylvia ^a   Ruhe, Jens E ^a   Hart, Stefan ^a   Lim, Kah Suan ^a   Loo, Hooi Linn ^a   Aung, Myat Oo ^b   Lim, Seng Gee ^b   Ullrich, Axel ^a,c  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Alpha fetoprotein; Apoptosis; FGFR4; HCC; Proliferation; Tyrosine kinase

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ALPHA FETOPROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL PROLIFERATION; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 56949101730     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.08.015     Document Type: Article

References (44)

1. Bosch F.X., Ribes J., Cleries R., and Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9 (2005) 191-211
2. Colombo M., and Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 60 (2003) 145-150
3. Llovet J.M. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40 (2005) 225-235
4. Arora A., and Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315 (2005) 971-979
5. Itoh S., Maeda T., Shimada M., Aishima S., Shirabe K., Tanaka S., et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res 10 (2004) 2812-2817
6. Qiu W.H., Zhou B.S., Chu P.G., Chen W.G., Chung C., Shih J., et al. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol 11 (2005) 5266-5272
7. Scharf J.G., and Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 35 (2003) 685-693
8. Sun C.K., Ng K.T., Sun B.S., Ho J.W., Lee T.K., Ng I., et al. The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer 97 (2007) 50-57
9. Zhang T., Sun H.C., Xu Y., Zhang K.Z., Wang L., Qin L.X., et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 11 (2005) 8557-8563
10. Lee S.C., Lim S.G., Soo R., Hsieh W.S., Guo J.Y., Putti T., et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics 16 (2006) 73-74
11. Su M.C., Lien H.C., and Jeng Y.M. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 224 (2005) 117-121
12. bou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
13. Lin A.Y., Fisher G.A., So S., Tang C., and Levitt L. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol 31 (2008) 84-88
14. Thomas M.B., Chadha R., Glover K., Wang X., Morris J., Brown T., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110 (2007) 1059-1067
15. Zhu A.X., Stuart K., Blaszkowsky L.S., Muzikansky A., Reitberg D.P., Clark J.W., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110 (2007) 581-589
16. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 (2005) 139-149
17. Wang J., Stockton D.W., and Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10 (2004) 6169-6178
18. Kan M., Wu X., Wang F., and McKeehan W.L. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 274 (1999) 15947-15952
19. Lin B.C., Wang M., Blackmore C., and Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282 (2007) 27277-27284
20. Xie M.H., Holcomb I., Deuel B., Dowd P., Huang A., Vagts A., et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11 (1999) 729-735
21. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160 (2002) 2295-2307
22. Wu X., Ge H., Gupte J., Weiszmann J., Shimamoto G., Stevens J., et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J Biol Chem 282 (2007) 29069-29072
23. Chomczynski P., and Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc 1 (2006) 581-585
24. Ruhe J.E., Streit S., Hart S., Wong C.H., Specht K., Knyazev P., et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 67 (2007) 11368-11376
25. Lee T.K., Poon R.T., Yuen A.P., Ling M.T., Kwok W.K., Wang X.H., et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12 (2006) 5369-5376
26. Ho H.K., Hu Z.H., Tzung S.P., Hockenbery D.M., Fausto N., Nelson S.D., et al. BCL-xL overexpression effectively protects against tetrafluoroethylcysteine-induced intramitochondrial damage and cell death. Biochem Pharmacol 69 (2005) 147-157
27. Huang X., Yang C., Luo Y., Jin C., Wang F., and McKeehan W.L. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 56 (2007) 2501-2510
28. Tsou A.P., Wu K.M., Tsen T.Y., Chi C.W., Chiu J.H., Lui W.Y., et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 50 (1998) 331-340
29. Yu C., Wang F., Kan M., Jin C., Jones R.B., Weinstein M., et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275 (2000) 15482-15489
30. Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M., et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62 (2002) 840-847
31. da Costa Andrade V., Parise Jr. O., Hors C.P., Melo Martins P.C., Silva A.P., and Garicochea B. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 82 (2007) 53-57
32. Morimoto Y., Ozaki T., Ouchida M., Umehara N., Ohata N., Yoshida A., et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98 (2003) 2245-2250
33. Streit S., Bange J., Fichtner A., Ihrler S., Issing W., and Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111 (2004) 213-217
34. Kuhlmann W.D., and Peschke P. Hepatic progenitor cells, stem cells, and AFP expression in models of liver injury. Int J Exp Pathol 87 (2006) 343-359
35. Abelev G.I., and Eraiser T.L. Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol 9 (1999) 95-107
36. Yokoo H., Kondo T., Fujii K., Yamada T., Todo S., and Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 40 (2004) 609-617
37. Buchler P., Reber H.A., Roth M.M., Shiroishi M., Friess H., and Hines O.J. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia 9 (2007) 119-127
38. Ezzat S., Huang P., Dackiw A., and Asa S.L. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11 (2005) 1336-1341
39. Koziczak M., Holbro T., and Hynes N.E. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23 (2004) 3501-3508
40. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17 (1998) 5896-5904
41. Trudel S., Ely S., Farooqi Y., Affer M., Robbiani D.F., Chesi M., et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103 (2004) 3521-3528
42. Fuchs B.C., Fujii T., Dorfman J.D., Goodwin J.M., Zhu A.X., Lanuti M., et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68 (2008) 2391-2399
43. Hopfner M., Sutter A.P., Huether A., Schuppan D., Zeitz M., and Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 41 (2004) 1008-1016
44. Weinstein M., Xu X., Ohyama K., and Deng C.X. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125 (1998) 3615-3623